ophthalmology-summit-2019-scientifictracks

Ophthalmology Summit 2019

Ophthalmology Case Reports | Volume 3

Note:

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

March 27-28, 2019 | Amsterdam, Netherlands

GLOBAL

OPHTHALMOLOGY SUMMIT 2019

Page44

LONG TERM OCULAR EFFECTS OF ANTI-VASCULAR ENDOTHELIAL GROWTH

FACTOR (RANIBIZUMAB) FOR RETINOPATHY OF PREMATURITY

Nisreen Albalushi, Nasra Al-Habsi, Chandrashakir, Gupta Lokesh

and

Yousif Al-Ahmer

Oman Medical Specialty Board, Oman

bjective of the study is to study the ocular and systemic effects of ranibizumab in patients with retinopa-

thy of prematurity and to find out if any ocular and systemic side effects documented due to ranibizumab

injection. The study is retrospective case series (from January 2014 to May 2016) and included all premature

children with the diagnosis of ROP who received anti VEGF (lucentis) for ROP. The study was conducted in a

tertiary hospital (AL-Nahdha Hospital) . Patient with leukocoria or with congenital eye anomaly were excluded

from the study. Demographic data were collected which include; DOB, gender, birth weight, birth history,

neonatal history (oxygen exposure), and type of ROP. The data were collected by reviewing patients’ files in

the hospital information system (Al-Shifa). All the diagnoses of retinopathy of prematurity were collected. A

well-designed data collection sheet was prepared using EpiData software to enter the data. It was found that

all patients had regressed ROP except 8 patients (9.6%) in their six months follow ups while after one year

follow up it was found that all patients had regressed ROP except two patients (2.4%) After six months follow

up it was found that none of the patients had cataract, three patients (3.6%) had strabismus, five patients (6%)

had myopia, one patient (1.2%) had amblyopia and one patient (1.2%) had retinal detachment. After one year

follow up it was found that one patient (1.2%) had cataract, seven patients (8.4%) had strabismus, six patients

(7.2%) had myopia, one patient (1.2%) had amblyopia and one patient (1.2%) had retinal detachment. No sys-

temic complications were documented. In conclusion, Few cases from the study were found to have ocular side

effects and no systemic side effects were reported. Ranibizumab intravitreal injection was found to be clinically

effective in treating patients with retinopathy of prematurity.

Nisreen Albalushi et al., Ophthalmol Case Rep 2019, Volume 3

Nisreen Albalushi graduated from Oman Medical College in 2013 by the age of 25 years old and did her internship in

obstetrics and gynecology, medicine and surgery. Worked as a medical officer in medicine and pediatrics from 2014

until she joined residency in ophthalmology program in Oman Medical Specialty Board. She is currently in her fourth

year of residency which is the surgical year of the program. She had one poster presented in international conference

of surgical glaucoma in Muscat-Oman: Glaucoma following congenital cataract surgery- case series from Al-Nahdha

Hospital, a tertiary eye center in Oman.

BIOGRAPHY